Sana Biotechnology

SANA · NASDAQ

$2.36+$0.06 (+2.61%)TodayMarket closed · Oct 20, 7:44 PM ET

Prev close $2.30

About SANA

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 142 full-time employees. The company went IPO on 2021-02-04. The company is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), oncology, and B cell mediated autoimmune diseases. The company develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline products include SC451 and UP421. SC451 is its HIP-edited product candidate for the treatment of type 1 diabetes. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. Its ex vivo cell engineering platform is focused on engineering hypoimmune cells that engraft, function, and persist in patients by evading immune rejection.

Employees: 142
Headquarters: Seattle, Washington
Listed: Feb 4, 2021
Sector: Health Care
Industry: Biotechnology
Website: sana.com

Leadership

Sana Biotechnology executives
Name	Title	Since	Age
Hans Bishop	—	—	61
Steven Harr	—	2018	54
Richard Mulligan	—	2018	70
Brian Piper	—	—	54
Tricia Stewart	—	—	—
Aaron Grossman	—	—	—
Joshua Bilenker	—	—	53
Douglas Cole	—	—	64
Robert Nelsen	—	—	61
Alise Reicin	—	—	64
Michelle Seitz	—	—	59
Patrick Yang	—	—	77

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Sana Biotechnology suppliers and customers
Company	Relationship	Country	Correlation
Beam Therapeutics BEAM	Supplier and customer	US	0.87
Innovent Biologics	Supplier and customer	CN	0.87
FUJIFILM Holdings	Supplier and customer	JP	0.75
Flagship Pioneering	Supplier and customer	US	—
Hadassah, The Women's Zionist Organization of America, Inc.	Supplier	US	—
Harvard University	Supplier and customer	US	—
United States	Supplier and customer	US	—
University of California	Supplier and customer	US	—
University of Rochester	Supplier and customer	US	—
University of Washington	Supplier and customer	US	—

Similar companies

Companies in the same industry as Sana Biotechnology

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.